IPM Take
Obesity drug development is becoming a contest over more than kilograms lost.
Survodutide, Boehringer Ingelheim and Zealand Pharma’s investigational glucagon/GLP-1 receptor dual agonist, has now delivered positive Phase III results in people living with both obesity and type 2 diabetes, one of the populations in which substantial weight reduction can be more difficult to achieve.
The company’s headline figure is striking: up to 13.1% mean weight loss after 76 weeks, compared with 3.1% with placebo. But that figure comes from the efficacy estimand, which asks what the effect would look like if participants remained on treatment for the study duration.
The peer-reviewed New England Journal of Medicine publication gives the more pragmatic treatment-regimen estimate as well. Under that analysis, which incorporates treatment discontinuation, interruptions and other obesity therapies, mean weight loss was 8.2% with 3.6 mg, 9.8% with 6.0 mg and 3.9% with placebo.
Both are legitimate analyses.
But they answer different questions.
And in a market where efficacy figures can increasingly look like competitive scoreboards, that distinction matters for regulators, payers and patients.
Survodutide also improved HbA1c, waist circumference and markers of insulin sensitivity. Yet gastrointestinal adverse effects remain important, with the company reporting treatment discontinuation because of GI events in 18% of survodutide-treated participants compared with 1.2% receiving placebo.
The next decisive evidence may therefore come from somewhere else entirely.
Boehringer says results from the dedicated SYNCHRONIZE-CVOT cardiovascular outcomes trial are expected later in 2026.
For a next-generation obesity therapy, weight loss gets attention.
Cardiovascular outcomes may determine value.
Executive Summary
SYNCHRONIZE-2 was a multinational, double-blind Phase III trial comparing once-weekly survodutide at 3.6 mg or 6.0 mg with placebo in adults with type 2 diabetes and a BMI of at least 27 kg/m². The peer-reviewed analysis included 752 participants and evaluated treatment over 76 weeks.
Using the treatment-regimen estimand, mean weight change was:
- -8.2% with survodutide 3.6 mg
- -9.8% with survodutide 6.0 mg
- -3.9% with placebo
At least 5% weight loss was achieved by 57.6%, 64.5% and 35.1% of participants, respectively.
The efficacy estimand, which assumes continued treatment, produced larger effects. Boehringer reported weight loss of up to 13.1%, versus 3.1% with placebo, and at least 5% weight loss in up to 79.3% of treated participants.
HbA1c also improved. In the published treatment-regimen analysis, mean change from a baseline of 7.4% was -0.9 percentage points with 3.6 mg, -0.8 points with 6.0 mg and -0.2 points with placebo. The company reported reductions of up to 1.21 percentage points under the efficacy estimand.
Survodutide remains investigational and is not approved for clinical use.
Why it matters
- HTA bodies: The trial demonstrates clinically relevant weight and glycaemic effects, but future assessment will need to distinguish between efficacy under continued treatment and effectiveness when discontinuation is included. Comparative value will also depend on cardiovascular, liver and kidney outcomes rather than weight loss alone.
- Payers: An increasingly crowded incretin market means payers are unlikely to judge new entrants solely by percentage weight loss. Persistence, adverse-event discontinuation, diabetes control and prevention of expensive downstream complications could become central to reimbursement and contracting decisions.
- Industry / innovation partners: Survodutide adds another mechanism to the next-generation incretin race. Its glucagon component is intended to complement GLP-1 effects on appetite and glucose regulation, while potentially influencing liver fat and energy metabolism. Whether that translates into differentiated clinical outcomes remains the strategic question.
The next obesity drug race is producing bigger numbers.
But the numbers are becoming harder to interpret.
At EASD 2026, Boehringer Ingelheim presented Phase III data showing that survodutide, an investigational dual agonist targeting both the glucagon and GLP-1 receptors, produced substantial weight reduction in adults with obesity or overweight and type 2 diabetes.
The company highlighted mean weight loss of up to 13.1% after 76 weeks, compared with 3.1% on placebo.
That result is real.
But it is not the only result.
One trial, two ways of measuring weight loss
Modern obesity trials increasingly report multiple estimands because treatment discontinuation complicates interpretation.
SYNCHRONIZE-2 used both an efficacy estimand and a treatment-regimen estimand.
The efficacy estimand estimates what might happen if patients remained on assigned treatment throughout the trial.
The treatment-regimen estimand incorporates what actually happens when participants discontinue or interrupt treatment or use other obesity therapies.
In the NEJM publication, the treatment-regimen analysis showed mean weight reductions of 8.2% with 3.6 mg survodutide and 9.8% with 6.0 mg, versus 3.9% with placebo.
The difference between roughly 10% and 13% is not a contradiction.
It reflects two different clinical questions.
One asks how well the drug works under continued exposure.
The other moves closer to what happens when real treatment interruptions are counted.
For health systems, the second question may become increasingly important.
The diabetes result matters as much as the weight result
Survodutide is not being developed only as a weight-loss drug.
Participants entered SYNCHRONIZE-2 with a mean HbA1c of 7.4%. In the published analysis, HbA1c fell by approximately 0.8 to 0.9 percentage points with survodutide, compared with 0.2 points with placebo.
The company’s efficacy analysis showed an even larger reduction of up to 1.21 percentage points.
Waist circumference fell by as much as 11.1 cm under that analysis, compared with 3.5 cm with placebo. Improvements were also reported in fasting glucose, insulin resistance and beta-cell function markers.
Almost 30% of participants receiving survodutide reached an HbA1c below 5.7% during treatment under the efficacy estimand, compared with 4% on placebo.
Those results support the idea that glucagon/GLP-1 dual agonism may influence several parts of metabolic disease simultaneously.
But surrogate improvements are not the same thing as proving long-term cardiovascular protection.
Why add glucagon?
At first glance, glucagon might seem like an unusual target in diabetes.
Glucagon can increase hepatic glucose production, historically making excess glucagon signalling part of the pathophysiology clinicians seek to control.
Survodutide attempts to exploit a more complicated biology.
The compound activates both glucagon and GLP-1 receptors. GLP-1 activity reduces appetite and improves glucose-dependent insulin secretion, while controlled glucagon-receptor activity may influence energy expenditure and liver metabolism.
The hypothesis is that the balance between the two signals could produce greater metabolic effects without losing glycaemic control.
The SYNCHRONIZE-2 results provide clinical evidence that blood glucose control can indeed improve despite glucagon-receptor agonism.
That makes survodutide scientifically interesting beyond its place in the weight-loss leaderboard.
Fat quality may become another battleground
Additional EASD data from a 75-person MRI substudy of SYNCHRONIZE-1 also point toward another emerging question in obesity medicine: what tissue is actually being lost?
Boehringer reported preferential reductions in visceral and liver fat, with muscle accounting for no more than 10% of total tissue lost in the substudy.
Those findings are potentially important because visceral adiposity and ectopic liver fat are strongly linked to cardiometabolic risk.
But the substudy was small, and it came from SYNCHRONIZE-1, which enrolled people without type 2 diabetes.
The result should therefore be viewed as supportive mechanistic evidence, not proof that body-composition differences will translate into fewer clinical events.
Tolerability remains part of the efficacy story
The other major issue is gastrointestinal tolerability.
In the published SYNCHRONIZE-2 analysis, gastrointestinal adverse events occurred in 72.8% of participants receiving 3.6 mg and 77.7% receiving 6.0 mg, compared with 38.6% with placebo. Most were described as mild to moderate and transient.
More consequentially, the company reported that 18% of people receiving survodutide discontinued treatment because of gastrointestinal adverse events, compared with 1.2% in the placebo group.
Boehringer notes that the study protocol provided limited flexibility during dose escalation and says later trials allow more patient-centred titration.
That will matter.
A therapy can produce impressive efficacy among patients who remain on treatment while delivering less benefit at population level if large numbers stop taking it.
For payers and health systems considering chronic obesity treatment, persistence is not a side issue.
It is part of effectiveness.
The cardiovascular outcome is still missing
This is where survodutide’s positioning remains unfinished.
Boehringer has enrolled a dedicated Phase III cardiovascular outcomes trial, SYNCHRONIZE-CVOT, in adults with overweight or obesity and cardiovascular disease, chronic kidney disease or cardiovascular risk factors.
The company says results are expected later in 2026.
That study could be decisive.
The obesity market increasingly contains medicines capable of producing major reductions in weight and HbA1c. Differentiation is therefore moving toward harder questions: cardiovascular outcomes, kidney protection, liver disease, tolerability, muscle preservation and long-term persistence.
Survodutide is already being developed across several of those domains, including obesity, type 2 diabetes and MASH. It has FDA Breakthrough Therapy designation and EMA PRIME status for development in MASH, but remains investigational.
The Phase III weight-loss data establish that the drug has a meaningful metabolic effect.
They do not yet establish where it belongs in the cardiometabolic treatment hierarchy.
That may be the more important question.
In an increasingly crowded obesity market, losing weight gets a drug into the conversation. Proving what happens to the heart, liver, kidneys and patient over years may determine whether it stays there.
